Menu
POTENTIAL DEAL DETAILS
| Stock | Tetraphase Pharmaceuticals, Inc. | Symbol | TTPH |
| Date Announced | 05/14/2020 | Source | Press Release |
| Type | Unsolicited Bid | Acquiring Company/Person | La Jolla Pharmaceutical Company |
| Date of Confirmation: | 06/24/2020 | Price at Confirmation: | $2.62 |
| Potential Profit: | 19.63% | Annualized Profit: | 174.80% |
Tetraphase Pharmaceuticals, Inc. (TTPH) received an unsolicited proposal from Melinta Therapeutics, Inc. (MLNTQ) to acquire Tetraphase for $27.0 million in cash, plus an additional $12.5 million in cash potentially payable under contingent value rights to be issued in the transaction.
Update(s):
June 22, 2020: Tetraphase (TTPH) Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta.
Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.